Quarterly report pursuant to Section 13 or 15(d)

Deferred Revenue

v3.4.0.3
Deferred Revenue
3 Months Ended
Mar. 31, 2016
Deferred Revenue Disclosure [Abstract]  
Deferred Revenue

8.

DEFERRED REVENUE

In May 2015, the Company received $1,250,000 upon signing the CFFT award agreement and in the fourth quarter of 2015, the Company received $1,250,000 from CFFT upon the achievement of a milestone for dosing the first patient (See Note 3 and Note 13).  The Company recorded these amounts as deferred revenue and is amortizing the deferred revenue and recognizing revenue on a straight-line basis over the performance period for the development program, which is expected to conclude during the first quarter of 2017. For the three months ended March 31, 2016 and 2015, the Company recorded revenue of $396,598 and $0, respectively. Deferred revenue consisted of the following:

 

 

 

March 31,

 

 

December 31,

 

 

 

2016

 

 

2015

 

Deferred revenue

 

 

1,455,020

 

 

$

1,851,618

 

Less: current portion

 

 

(1,455,020

)

 

 

(1,591,358

)

Long-term portion

 

$

 

 

$

260,260